SPECGX LLC - NEW AWARD FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC . PERIOD OF PERFORMANCE IS MAY 27, 2023 THROUGH MAY 26, 2024 WITH FOUR ONE YEAR OPTION YEARS.
Key Details
Description
NEW AWARD FOR ATROPINE/DIPHENOXYLATE HCL TABLETS WITH SPECGX, LLC . PERIOD OF PERFORMANCE IS MAY 27, 2023 THROUGH MAY 26, 2024 WITH FOUR ONE YEAR OPTION YEARS.
Context & Analysis
On Dec 31, 2025, Department of Veterans Affairs to SPECGX LLC for new award for atropine/diphenoxylate hcl tablets with specgx, llc . period of performance is may 27, 2023 through may 26, 2024 with four one year option years.. The award is classified under NAICS 325412 — PHARMACEUTICAL PREPARATION MANUFACTURING and issued as a firm fixed price contract. Competition extent: full and open competition with 4 offers received. The procurement used a NO SET ASIDE USED. set-aside. This award is one of several similar procurements from Department of Veterans Affairs under NAICS 325412 — related awards are listed below.
Contractor Information
Similar Awards
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 NOVEMBER
MCKESSON CORPORATION
$1.4B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 OCTOBER
MCKESSON CORPORATION
$1.2B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 DECEMBER
MCKESSON CORPORATION
$1.1B
EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2026 JANUARY
MCKESSON CORPORATION
$1.1B
LENALIDOMIDE FOR THE SALISBURY VAMC, CHARLOTTE HCC, AND KERNERSVILLE HCC.
EXELAN PHARMACEUTICALS INC
$5.1M
Stay Updated
Get notified about new opportunities matching your interests.